Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer
- 1 July 2007
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 68 (3) , 690-698
- https://doi.org/10.1016/j.ijrobp.2006.12.064
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatmentProstate Cancer and Prostatic Diseases, 2006
- Influence of Dose Volume Histogram (DVH) Pattern on Rectal ToxicityInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose–volume constraints to achieve rectal isotoxicityInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiationInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 GyInternational Journal of Radiation Oncology*Biology*Physics, 2005
- HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCERJournal of Urology, 2001
- Portal film analysis of an escalated dose conformal prostatic irradiation protocol using fiducial markers and portal images to confirm target organ and isocentre positionInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspectiveUrology, 1996
- Late rectal bleeding following combined x-ray and proton high dose irradiation for patients with stages T3–T4 prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1993